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Abstract
Background: To investigate whether atherogenic index of plasma (AIP) at diagnosis is associated with the
occurrence of cerebrovascular accident (CVA) or coronary artery disease (CAD) in antineutrophil cytoplasmic
antibody-associated vasculitis (AAV).
Methods: The medical records of 167 AAV patients on initial diagnosis was reviewed, and 300 healthy controls
were included. AIP was calculated using the following equation: AIP = Log (triglyceride [mg/dL] / high-density
lipoprotein cholesterol [mg/dL]). AAV patients were divided into two groups according to the AIP cut-off of 0.11.
The event of stroke, transient ischemic attack, and cerebral hemorrhage was recorded as CVA, and CAD events
consisted of either myocardial infarction and angina pectoris. CVA- and CAD- free survival rate between those with
AIP ≥ 0.11 and < 0.11 were compared by the Kaplan-Meier analysis, and Cox hazard analysis was conducted to
identify predictors of CVA.
Results: The median age of AAV patients were 59.0 years, and 54 (32.3%) patients were male. One-hundred and
fifteen (68.9%) patients had AIP < 0.11 and 52 (31.1%) had AIP ≥ 0.11. The mean Birmingham vasculitis activity score
in AAV patients with AIP < 0.11 was lower than that seen in patients with AIP ≥ 0.11 (12.0 vs. 14.0, P = 0.041). AAV
patients had a significantly higher AIP compared to controls (mean − 0.01 vs. -0.10, P < 0.001). During follow-up, the
occurrence of CVA and CAD was observed in 16 (9.6%) and 14 (8.4%) patients, respectively. In Kaplan-Meier analysis,
AAV patients with AIP ≥ 0.11 had significantly lower CVA-free survival rates than in those with AIP < 0.11 (P = 0.027),
whereas there was no difference in CAD according to AIP (P = 0.390). Multivariable Cox analysis indicated that
AIP ≥ 0.11 at diagnosis was the sole predictor of CVA (Hazard ratio 3.392, 95% confidence interval 1.076, 10.696, P =
0.037).
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Conclusions: AIP is significantly higher in AAV patients than in healthy controls, and AIP ≥ 0.11 at diagnosis is a
significant predictor of CVA during follow-up. Stringent surveillance should be provided in AAV patients with AIP ≥
0.11 regarding the occurrence of CVA.
Trial registration: Retrospectively registered (4–2017-0673).
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Background
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a chronic inflammatory disorder
(CID) that usually involves the small-sized vasculatures
and has three distinct subtypes: microscopic polyangiitis
(MPA), granulomatosis with polyangiitis, and eosino-
philic granulomatosis with polyangiitis [1, 2]. Generally,
AAV involves the vessels and induces necrotizing vascu-
litis within the arterioles, venules, and capillaries and
could present with a wide spectrum of clinical manifes-
tations [3]. Even though the pathogenesis of AAV is
thought to be complex, it is now being increasingly
understood that a breach of cellular and humoral
immunity is responsible for the loss of self-tolerance,
leading to inflammation and organ injury [4]. In
addition, the overproduction of pro-inflammatory
cytokines, such as tumor necrosis factor (TNF)-α,
interferon-gamma, interleukin (IL)-1b, IL-6, IL-8, and
IL-18, is responsible for amplifying the vicious loop [5].
Chronic inflammation is generally associated with
deregulated lipid metabolism skewed towards an athero-
genic profile, and it is typically characterized by an in-
crease of triglyceride (TG) and decrease of high-density
lipoprotein (HDL)-cholesterol [6, 7]. Even though mul-
tiple factors have been suggested regarding this
phenomenon, the secretion of multiple inflammatory cy-
tokines, i.e. TNF, IL-1, IL-2, and IL-6, is reported to be
linked to the elevation of TG level, which is induced by
accelerated lipolysis in the adipose tissue and the synthe-
sis of fatty acids in the liver, while inhibiting hepatic
fatty acid oxidation [8]. On the other hand, pro-
inflammatory cytokines are also implicated in the de-
crease of HDL-cholesterol as a consequence of impaired
production of apolipoprotein A-1, which is a major pro-
tein constituting the HDL-cholesterol [9]. Moreover, di-
minished formation of cholesterol ester, structural and
functional alteration of HDL-cholesterol, and increased
HDL-cholesterol clearance have been also thought be
relevant to the decreased HDL-cholesterol level in the
presence of chronic inflammation [7].
Emerging evidences now clearly indicate that patients
with CID are prone to cardiovascular diseases (CVD)
such as cerebrovascular accident (CVA), coronary artery
disease (CAD), and thromboembolic diseases [10–12].
Notably, atherogenic index of plasma (AIP), which is cal-
culated based on serum TG and HDL-cholesterol, is one
of the laboratory indices indicating atherogenic status,
and this has been used to assess the extent of dyslipid-
emia and predict the potential of developing CVA and
CAD in various medical conditions [13–15]. Given that
patients with CID are more often affected by CVDs than
in healthy subjects and that increase of TG and decrease
of HDL-cholesterol is present in those with chronic in-
flammation, it is possible that AIP is elevated in AAV
patients and is associated with CVA and CAD. However,
there have been no studies that determined the predict-
ive potential of AIP regarding CVA and CAD events in
AAV. Hence, this study investigated whether AIP in pa-
tients with AAV is higher than that in controls and to




The medical records of 216 AAV patients when the
initial diagnosis was made, were retrospectively
reviewed. Patients were classified as AAV at the Division
of Rheumatology in Severance Hospital, during the
period from October 2000 to December 2019, based on
the 2007 European Medicines Agency algorithm and the
2012 Chapel Hill Consensus Conferences definitions [1,
16]. The patients had well-documented medical records
with accessible clinical and laboratory results, including
Birmingham vasculitis activity score (BVAS) and five-
factor score (FFS) [17, 18]. ANCA was detected using in-
direct immunofluorescence assay and antigen-specific
enzyme-linked immunosorbent assays for myeloperoxi-
dase and proteinase 3. When the patients did not have
ANCAs detected, the diagnosis of ANCA-negative
vasculitis was made based on the clinical features and/or
the histologic findings. All study subjects were followed
up for at least 3 months after the diagnosis of AAV. At
the time of diagnosis, patients were not on immunosup-
pressive agents and were not on medications to treat
dyslipidemia. Further characteristics that would lead to a
false-positive ANCA result, such as coexisting
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malignancies and serious infections, were also consid-
ered as exclusion criteria. Of the 216 AAV patients, 37
were excluded because TG and HDL-cholesterol levels
were not assessed. Furthermore, 12 patients were
currently taking drugs to treat dyslipidemia. Finally, 167
patients were included and analyzed in this study. In
addition, body mass index (BMI) and lipid levels of TG,
HDL-cholesterol, and low-density lipoprotein (LDL)-
cholesterol from 300 age- and gender-matched healthy
controls, who had visited the healthcare center in Sever-
ance Hospital for a routine health examination and were
not on medications to treat dyslipidemia, were assessed.
The Institutional Review Board of Severance Hospital
approved this study and was performed according to the
ethical guidelines set forth in the Declaration of Helsinki
(4–2017-0673).
Baseline data and the definition of clinical outcomes
Patients’ demographic data such as age, gender, BMI,
smoking history, and AAV subtypes were collected.
ANCA positivity as well as AAV-specific indices of
BVAS and FFS were obtained. Clinical manifestations
and the presence of comorbidities, such as chronic
kidney disease (stage III–V), diabetes mellitus, hyperten-
sion, and interstitial lung disease, were also assessed. In
addition, the laboratory results including acute phase
reactants of erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) level, as well as AIP-related vari-
ables ─ serum total cholesterol, TG, HDL-cholesterol,
and LDL-cholesterol levels ─ were reviewed. The clin-
ical outcomes evaluated during the follow-up consisted
of all-cause mortality, CVA, and CAD. In this study, we
defined all-cause mortality as death regardless of the
cause. We included events of cerebral infarction, transi-
ent ischemic attack, and cerebral hemorrhage as CVA
and included acute coronary syndrome, including myo-
cardial infarct and angina pectoris, as CAD. The follow-
up duration was defined as the duration between the
date of AAV diagnosis until the occurrence of clinical
outcomes or the last visit, when subjects did not have an
event corresponding to clinical outcomes.
Calculation of AIP
AIP was calculated using the following equation: AIP =
Log (TG (mg/dL) / HDL-cholesterol (mg/dL)), as
described previously [13]. Based on the results from
previous studies, patients could be divided into three
categories based on their AIP value. An AIP < 0.11 as
low risk, AIP of 0.11–0.21 as intermediate risk, and
AIP > 0.21 as high risk [19, 20]. In this study, AAV
patients were divided into two groups according to AIP
as follows: AAV patients with AIP < 0.11 (N = 115) and
AAV patients with AIP ≥ 0.11(N = 52).
Statistical analyses
Continuous variables that were normally distributed are
expressed as mean (standard deviation) and as median
(interquartile range) when non-normally distributed.
Categorical variables are expressed as number and the
percentage. Significant differences between continuous
variables were assessed using Student’s t-test, Mann-
Whitney U test, and analysis of variance, whereas differ-
ences between the categorical variables were analyzed by
the Chi-square and Fisher’s exact tests, as appropriate.
Associations and the correlation coefficient between
continuous variables were derived using the Pearson
correlation analysis or Spearman correlation analysis.
Comparison of the clinical outcome free survivals rates
were analyzed using the Kaplan-Meier analysis with the
log-rank test. Multivariable Cox hazards analysis was
carried out using variables that showed statistical signifi-
cance in the univariable analysis to identify predictors of
CVA by the forward entry method. A P-value < 0.05 was
considered statistically significant. All statistical analyses
were conducted using SPSS software version 23 for
Windows (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics of AAV patients at baseline
Of the included 167 patients, the median age of the pa-
tients was 59 years, 54 (32.3%) were male, and the mean
BMI was 22.1 kg/m2, respectively. The most common
AAV subtype in the patients was MPA (N = 92, 55.1%),
and ANCA was detected in 133 patients (79.6%). The
most common clinical features were renal (62.3%) and
pulmonary (58.1%) manifestations; hypertension as a co-
morbid condition was most frequently (53.3%) observed.
The laboratory test results are shown in Table 1. The
mean calculated AIP was − 0.01, and 115 (68.9%) and 52
(31.1%) patients were included in the AIP < 0.11 and
AIP ≥ 0.11 group, respectively. Patients with AIP ≥ 0.11
had a higher BVAS compared to those with AIP < 0.11
(P = 0.041), even though there were no difference in FFS
(P = 0.656). However, total serum protein level was sig-
nificantly lower in patients with AIP ≥ 0.11 than in those
with AIP < 0.11 (6.7 mg/dL vs. 6.4 mg/dL, P = 0.043). As
for AIP-related variables, TG level was higher in the
AIP ≥ 0.11 group than in the AIP < 0.11 group, while the
level of HDL-cholesterol was lower (both P < 0.001)
(Table 1).
On comparing demographic and AIP-related variables
with healthy controls, AAV patients were found to have
a significantly lower BMI (P < 0.001) and higher TG and
HDL-cholesterol levels (median 113.0 mg/dL vs. 94.0
mg/dL, P = 0.002 and median 51.0 mg/dL vs. 50.0 mg/dL,
P = 0.016). Moreover, AAV patients exhibited a signifi-
cantly higher AIP value than controls (mean − 0.01 vs.
-0.10, P < 0.001) (Table 2).
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Table 1 Clinical characteristics of AAV patients at diagnosis
Variables All AAV patients
(N = 167)
AAV patients with AIP < 0.11
(N = 115)




Age (years) 59.0 (22.0) 60.0 (24.0) 56.0 (19.8)a 0.369
Male gender (N, (%)) 54 (32.3) 34 (29.6) 20 (38.5) 0.255
Body mass index (kg/m2) 22.1 (4.5)a 22.0 (4.8)a 23.2 (4.3)a 0.324
Smoking history (N, (%)) 6 (3.6) 3 (2.6) 3 (5.8) 0.310
AAV Subtypes (N, (%)) 0.641
MPA 92 (55.1) 64 (55.7) 28 (53.8)
GPA 38 (22.8) 24 (20.9) 14 (26.9)
EGPA 37 (22.2) 27 (23.5) 10 (19.2)
ANCA positivity (N, (%))
MPO-ANCA (or P-ANCA) positivity 114 (68.3) 79 (68.7) 35 (67.3) 0.858
PR3-ANCA (or C-ANCA) positivity 27 (16.2) 16 (13.9) 11 (21.2) 0.239
Both ANCA positivity 8 (4.8) 6 (5.2) 2 (3.8) 1.000
ANCA negativity 34 (20.4) 26 (22.6) 8 (15.4) 0.283
AAV-specific indices
BVAS 12.0 (11.0)a 12.0 (11.0)a 14.0 (10.0)a 0.041
FFS 1.0 (1.0) 1.0 (1.0) 1.0 (1.0) 0.656
Clinical manifestations (N, (%))
General 75 (44.9) 48 (41.7) 27 (51.9) 0.221
Cutaneous 38 (22.8) 29 (25.2) 9 (17.3) 0.259
Muco-membranous /Ocular 10 (6.0) 5 (4.3) 5 (9.6) 0.184
Ear nose throat 75 (44.9) 51 (44.3) 24 (46.2) 0.828
Pulmonary 97 (58.1) 69 (60.0) 28 (53.8) 0.455
Cardiovascular 43 (25.7) 27 (23.5) 16 (30.8) 0.318
Gastrointestinal 9 (5.4) 7 (6.1) 2 (3.8) 0.553
Renal 104 (62.3) 69 (60.0) 35 (67.3) 0.367
Nervous 56 (33.5) 38 (33.0) 18 (34.6) 0.842
Comorbidities (N, (%))
Chronic kidney disease (stage 3–5) 53 (31.7) 33 (28.7) 20 (38.5) 0.209
Diabetes mellitus 51 (30.5) 35 (30.4) 16 (30.8) 0.965
Hypertension 89 (53.3) 57 (49.6) 32 (61.5) 0.151
Interstitial lung disease 50 (29.9) 36 (31.3) 14 (26.9) 0.567
Laboratory results
White blood cell count (/mm3) 9210.0 (6347.5) 9180.0 (6430.0) 10,230.0 (6000.0) 0.927
Hemoglobin (g/dL) 11.3 (2.3)a 11.4 (2.3)a 11.0 (2.5)a 0.235
Platelet count (× 1000/mm3) 308.0 (166.0) 311.0 (158.5) 294.0 (195.0) 0.949
Fasting glucose (mg/dL) 104.0 (36.0) 103.0 (34.0) 106.0 (38.0) 0.466
BUN (mg/dL) 18.4 (22.4) 18.0 (23.0) 24.2 (21.6) 0.078
Creatinine (mg/dL) 1.0 (1.3) 0.9 (1.0) 1.3 (2.0) 0.105
Total serum protein (g/dL) 6.6 (1.3) 6.7 (1.1) 6.4 (1.0)a 0.043
Serum albumin (g/dL) 3.5 (0.8)a 3.5 (0.7)a 3.3 (0.8)a 0.068
ALP (IU/L) 72.0 (38.0) 69.0 (36.0) 77.0 (51.0) 0.339
AST (IU/L) 18.5 (9.0) 19.0 (8.0) 17.0 (10.0) 0.121
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Correlation of AIP with continuous variables
At AAV diagnosis, AIP was found to be positively corre-
lated with ESR (r = 0.171, P = 0.028), CRP (r = 0.169, P =
0.030), and blood urea nitrogen (r = 0.187, P = 0.016) and
negatively correlated with total serum protein and serum
albumin (r = − 0.201, P = 0.010 and r = − 0.209, P =
0.007). In addition, AIP was highly correlated with TG
and HDL-cholesterol (r = 0.770, P < 0.001 and r = −
0.579, P < 0.001). AIP was not significantly correlated
with age, BMI, BVAS, FFS, and the remaining laboratory
variables (Table 3).
Clinical outcomes and medications during follow-up
During the follow-up period, 18 patients died, and 16
and 14 patients experienced CVA and CAD events,
respectively. Concerning the medications used to treat
AAV, glucocorticoids were most frequently administered
(N = 155, 92.8%), followed by cyclophosphamide (N = 87,
52.1%) and azathioprine (N = 82, 49.1%) (Table 4).
Comparison of clinical outcomes between AAV patients
with AIP < 0.11 and those with AIP ≥ 0.11
Regarding clinical outcomes, AAV patients with AIP ≥
0.11 exhibited a significantly lower CVA-free survival
rate than those with AIP < 0.11 (P = 0.027). However,
there were no significant differences regarding all-cause
mortality and CAD between patients with AIP < 0.11
and AIP ≥ 0.11 (P = 0.357 and P = 0.390) (Fig. 1).
Cox hazards analysis for the prediction of CVA
To investigate whether AIP ≥ 0.11 at diagnosis could in-
dependently predict CVA occurrence during follow-up,
we compared the predictive potential of conventional
risk factors for CVA, ANCA types, AAV-specific indices,
acute phase reactants, and AIP using the Cox hazards
analysis. In the univariable analysis, both AIP ≥ 0.11
(Hazard ratio (HR) 3.391, 95% confidence interval (CI)
1.075, 10.695, P = 0.037) and CRP (HR 1.008, 95% CI
1.001, 1.016, P = 0.035) were significantly associated with
CVA during follow-up. In the multivariable analysis,
only AIP ≥ 0.11 at diagnosis was revealed to be signifi-
cantly associated with CVA during follow-up (HR 3.392,
95% CI 1.076, 10.696, P = 0.037) (Table 5).
Comparison of AIP according to gender, body mass
index, age, and AAV subtypes
To exclude the possibility of the influence of gender,
BMI, age, and AAV subtypes in AIP, a subgroup analysis
was performed. Male patients with AAV had
Table 1 Clinical characteristics of AAV patients at diagnosis (Continued)
Variables All AAV patients
(N = 167)
AAV patients with AIP < 0.11
(N = 115)
AAV patients with AIP ≥ 0.11
(N = 52)
P-value
ALT (IU/L) 16.5 (14.8) 15.0 (13.5) 19.0 (18.0) 0.985
Total bilirubin (mg/dL) 0.5 (0.3) 0.5 (0.3) 0.5 (0.4) 0.620
ESR (mm/hr) 64.0 (69.3) 64.0 (67.0) 66.8 (39.6)a 0.406
CRP (mg/L) 17.0 (85.8) 15.0 (69.3) 25.0 (119.3) 0.123
AIP-related variables
Total cholesterol (mg/dL) 178.0 (58.0) 182.1 (45.8)a 187.0 (58.1)a 0.561
TG (mg/dL) 113.0 (73.0) 97.5 (35.5)a 174.5 (67.8) < 0.001
HDL-cholesterol (mg/dL) 51.0 (23.0) 55.0 (25.0) 41.4 (14.6)a < 0.001
LDL-cholesterol (mg/dL) 104.6 (41.6) 106.0 (33.1)a 102.2 (45.1) 0.917
AIP −0.01 (0.2)a − 0.1 (0.3) 0.3 (0.1)a < 0.001
Values are expressed as a median (interquartile range) or N (%)
AAV ANCA-associated vasculitis, ANCA Antineutrophil cytoplasmic antibody, AIP Atherogenic index of plasma, MPA Microscopic polyangiitis, GPA Granulomatosis
with polyangiitis, EGPA Eosinophilic GPA, MPO Myeloperoxidase, P Perinuclear, PR3 Proteinase 3, C Cytoplasmic, BVAS Birmingham vasculitis activity score, FFS Five-
factor score, BUN Blood urea nitrogen, ALP Alkaline phosphatase, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ESR Erythrocyte sedimentation
rate, CRP C-reactive protein, TG Triglyceride, HDL High-density lipoprotein, LDL Low-density lipoprotein
a Normally distributed data are expressed as mean (standard deviation)
Table 2 Comparison of demographic data and AIP-related







Age (years) 59.0 (22.0) 58.0 (21.0) 0.382
Male gender (N, (%)) 54 (32.3) 82 (27.3) 0.254
Body mass index (kg/m2) 22.3 (3.1)a 23.3 (3.4) < 0.001
AIP-related variables
TG (mg/dL) 113.0 (73.0) 94.0 (60.0) 0.002
HDL-cholesterol (mg/dL) 51.0 (23.0) 50.0 (19.0) 0.016
LDL-cholesterol (mg/dL) 104.6 (41.6) 106.0 (48.0) 0.211
AIP −0.01 (0.2)a −0.10 (0.2)a < 0.001
Values are expressed as a median (interquartile range) or N (%)
AIP Atherogenic index of plasma, AAV ANCA-associated vasculitis, ANCA
Antineutrophil cytoplasmic antibody, TG Triglyceride, HDL High-density
lipoprotein, LDL Low-density lipoprotein
a Normally distributed data are expressed as mean (standard deviation)
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significantly higher AIP than female patients with AAV
(P = 0.026). However, there were no significant differ-
ences in AIP regarding BMI (divided based on the Asian
Pacific cut-off values) (P = 0.334) and age (P = 0.196)
[21]. Furthermore, AIP was not found to differ based on
AAV subtypes (P = 0.407) (Fig. 2).
Discussion
In line with the knowledge that patients with CIDs are
at increased risk of developing CVDs, several studies
have demonstrated that the risk of CVDs is heightened
in AAV patients. A long-term population-based study
revealed that the risk of CVD and CVA in AAV patients
were 3- and 8-fold higher than those in matched
subjects [22]. In addition, a retrospective study that was
performed in the United Kingdom has shown that AAV
patients have high incidence of arterial and venous
thrombosis [23]. Moreover, a meta-analysis by Houben
et al. demonstrated that the risk of developing
cardiovascular events was higher in AAV patients com-
pared to the general population [24]. Therefore, it is
clinically important to uncover predictors that could
help estimate the development of CVDs in AAV pa-
tients, as this could be a potentially life-threatening
event.
To the best of our knowledge, this is the first study
that evaluated the clinical effectiveness of using AIP to
predict CVA and CVD in AAV patients. Consistent with
what was initially expected, the observations from this
study demonstrated that AAV patients had significantly
higher AIP compared to healthy controls (0.01 vs. -0.12,
P < 0.001). Moreover, AAV patients with AIP ≥ 0.11 on
diagnosis exhibited significantly higher disease activity at
baseline, and the occurrence of CVA events during the
follow-up was more frequent compared to those with
AIP < 0.11. In addition, Cox hazards analysis revealed
that AIP ≥ 0.11 at diagnosis is an independent predictor
for CVA during follow-up, even when various conven-
tional risk factors for CVA, ANCA types, AAV-specific
indices, and acute phase reactants were taken into con-
sideration [17, 18, 25–28]. On the basis of the results of
this study, it could be suggested that the occurrence of
CVA should be actively monitored in AAV patients,
especially in those with AIP ≥ 0.11, when the initial diag-
nosis is established.
In the present study, the cut-off value of AIP ≥ 0.11
was adopted to predict de novo CVA events in AAV
patients; this was done since the number of patients with
Table 4 Outcomes and the medications administered in AAV
patients during follow-up
AAV patients Values
Clinical outcomes during follow-up (N, (%))
All-cause mortality (N, (%)) 18 (10.8)
Follow-up duration based on all-cause mortality (months) 33.7 (65.6)
CVA (N, (%)) 16 (9.6)
Follow-up duration based on CVA (months) 30.5 (64.0)
CVD (N, (%)) 14 (8.4)
Follow-up duration based on CVD (months) 32.8 (63.6)





Mycophenolate mofetil 22 (13.2)
Tacrolimus 11 (6.6)
Methotrexate 12 (7.2)
Values are expressed as a median (interquartile range, IQR) or N (%)
AAV ANCA-associated vasculitis, ANCA Antineutrophil cytoplasmic antibody,
CVA Cerebrovascular accident, CVD Cardiovascular disease




Body mass indexa 0.102 0.191
White blood cell count (/mm3) 0.080 0.309
Hemoglobin (g/dL)a −0.124 0.113
Platelet count (× 1000/mm3) 0.069 0.377
Fasting glucose (mg/dL) 0.117 0.133
BUN (mg/dL) 0.187 0.016
Creatinine (mg/dL) 0.141 0.071
Total serum protein (g/dL) −0.201 0.010
Serum albumin (g/dL)a −0.209 0.007
ALP (IU/L) 0.100 0.199
AST (IU/L) −0.093 0.237
ALT (IU/L) −0.036 0.647
Total bilirubin (mg/dL) 0.045 0.569
ESR (mm/hr) 0.171 0.028
CRP (mg/L) 0.169 0.030
Total cholesterol (mg/dL) −0.075 0.338
TG (mg/dL) 0.770 < 0.001
HDL-cholesterol (mg/dL) −0.579 < 0.001
LDL-cholesterol (mg/dL) −0.035 0.650
BVASa 0.124 0.111
FFS 0.093 0.232
AIP Atherogenic index of plasma, BUN Blood urea nitrogen, ALP Alkaline
phosphatase, AST Aspartate aminotransferase, ALT Alanine aminotransferase,
ESR Erythrocyte sedimentation rate, CRP C-reactive protein, TG Triglyceride,
HDL High-density lipoprotein, LDL Low-density lipoprotein, BVAS Birmingham
vasculitis activity score, FFS Five-factor score
a Normally distributed data
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AIP 0.11–0.21 (N = 20) and AIP > 0.21 was small (N =
32) and since the events of CVA and CAD were
observed in a relatively small number of patients. There-
fore, categorizing patients into the three different groups
of AIP < 0.11, AIP 0.11–0.21, and AIP > 0.21 could result
in a false negative result owing to a low statistical power.
Indeed, when the clinical outcomes were compared by
dividing the patients into three groups, the patients with
AIP < 0.11 were less likely to experience CVA compared
to those with AIP 0.11–0.21 and AIP > 0.21, even though
the risk of developing CVA was not directly incremental
(Fig. 3).
Previous studies have demonstrated a variable range of
AIPs, and variations could arise because of differences in
ethnicity, gender, geographical factors, and the medical
conditions investigated. A study by Zhu et al. has shown
that the mean AIP values in Chinese people with and
without obesity were 0.13 and − 0.04 [29]. On the other
Fig. 1 Comparison of the cumulative clinical outcome free survival rate in patients with AIP < 0.11 and AIP≥ 0.11. Among the clinical outcomes,
AAV patients with AIP≥ 0.11 exhibited a significantly lower cumulative CVA-free survival rate than those with AIP < 0.11, while there was no
difference regarding all-cause mortality and CAD. AIP: atherogenic index of plasma; AAV: ANCA-associated vasculitis; ANCA: antineutrophil
cytoplasmic antibody; CVA: cerebrovascular accident; CAD: coronary artery disease
Table 5 Predictors for the occurrence of CVA during follow-up
Variables Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Demographic data
Age (years) 1.027 0.982, 1.074 0.243
Male gender 0.862 0.259, 2.874 0.809
Body mass index (kg/m2) 0.991 0.826, 1.190 0.924
Smoking history 0.047 0.000, 32,787.590 0.656
Comorbidities
Chronic kidney disease (stage 3–5) 1.069 0.322, 3.551 0.914
Diabetes mellitus 1.527 0.484, 4.810 0.470
Hypertension 1.636 0.492, 5.442 0.422
ANCA positivity
MPO-ANCA (or P-ANCA) positivity 0.678 0.215, 2.142 0.508
PR3-ANCA (or C-ANCA) positivity 1.041 0.228, 4.760 0.958
AAV-specific indices
BVAS 1.074 0.995, 1.160 0.066
FFS 1.476 0.851, 2.559 0.165
Acute phase reactants
ESR (mm/hr) 1.001 0.986, 1.017 0.860
CRP (mg/L) 1.008 1.001, 1.016 0.035
AIP ≥ 0.11 3.391 1.075, 10.695 0.037 3.392 1.076, 10.696 0.037
CVA Cerebrovascular accident, ANCA Antineutrophil cytoplasmic antibody, MPO Myeloperoxidase, P Perinuclear, PR3 Proteinase 3, C Cytoplasmic, BVAS Birmingham
vasculitis activity score, FFS Five factor score, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, AIP Atherogenic index of plasma
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hand, Wu et al. identified the mean value of AIP in post-
menopausal women with CAD and without CAD as 0.20
and 0.10, respectively; furthermore, a study that
estimated AIP in subjects undergoing chronic dialysis re-
ported median values of AIP as 0.47 [13, 30]. Notably,
several studies have been performed to evaluate AIP
levels in CIDs, and a study that compared AIP levels in
patients with SLE and controls showed that SLE patients
had significantly higher AIP levels than controls, which
is consistent with the result of this study [31]. Moreover,
it was also described that AIP could be a predictor of
subclinical atherosclerosis, particularly carotid artery
intima-media thickness, in subjects with SLE, Behçet dis-
ease, and ankylosing spondylitis, emphasizing that sub-
jects with higher AIP could be more vulnerable to CVA
among patients with CIDs [31–33]. However, as most of
the studies that were performed in patients with CIDs
did not directly evaluate the incidence of CVAs, add-
itional research is necessary to determine the relation-
ship between AIP and CVAs in CIDs.
Fig. 2 Comparison of AIP based on gender, body mass index, age, and AAV subtypes. Male patients with AAV exhibited a higher AIP than female
patients with AAV. However, no significant differences in AIP according to body mass index, age, and AAV subtypes were found. AIP: atherogenic
index of plasma; AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; MPA: microscopic polyangiitis; GPA: granulomatosis
with polyangiitis; EGPA: eosinophilic GPA
Fig. 3 Comparison of the cumulative clinical outcome free survival rate based on the different cut-off of AIP. The frequency of CVA seemed to be
higher in patients with AIP 0.11–0.21 and AIP ≥ 0.21 compared to those with AIP < 0.11, although statistical significance has not been reached.
CVA: cerebrovascular accident; AIP: atherogenic index of plasma; CAD: coronary artery disease
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Besides AIP, previous data have proposed that higher
cholesterol levels, such as TC, LDL-cholesterol, and TG
could be used to predict the incidence of CVDs, even
though inconsistent results were obtained across studies
[34–37]. Accordingly, when the predictive value of dif-
ferent laboratory measures comprising AIP was investi-
gated, AIP ≥ 0.11 and HDL-cholesterol were found to be
significantly associated with the incidence of CVA. How-
ever, given that AIP and HDL-cholesterol are closely as-
sociated because AIP level also includes the level of
HDL-cholesterol in its calculation, further research is
necessary to identify which is the most appropriate
measure in estimating CVAs in AAV.
It has been acknowledged that higher disease activ-
ity is generally associated with increased risk of CVDs
in patients with CIDs [38, 39]. Accordingly, on com-
paring the baseline characteristics of patients with
AIP ≥ 0.11 and AIP < 0.11, it was found that the dif-
ference of BVAS between the groups was significant
(P = 0.041). Furthermore, in regard to the medications
administered during follow-up, both cyclophospha-
mide (63.5% vs. 47.0%, P = 0.048) and rituximab
(26.9% vs. 13.0%, P = 0.028) were administered more
commonly to AAV patients with AIP ≥ 0.11 than to
those with AIP < 0.11 (Table 6). Based on the recom-
mendations for the management of AAV, either
cyclophosphamide or rituximab together with gluco-
corticoid should be given to AAV patients with life-
threatening disease [40]. Taken together, it can be
speculated that the inflammatory burden in AAV pa-
tients with AIP ≥ 0.11 is significantly higher than that
of patients with AIP < 0.11 during follow-up, leading
to an increased risk for CVA. In particular, it should
be noted that the sum of the inflammatory burdens
could not be simply estimated through BVAS, which
consists of multiple measures that may not properly
indicate the dynamic changes of vascular inflamma-
tion [41].
A previous study suggested that the major factors
influencing AIP were gender, obesity, and older age
[42]. Accordingly, in this study, a subgroup analysis
was performed to determine whether these factors af-
fected the level of AIP. Of note, even though it was
also revealed that male AAV patients exhibited sig-
nificantly elevated AIP levels compared with females,
which is similar to the previous studies, AIP was not
found to differ based on BMI, age, and disease sub-
types in the present study. Even though this discrep-
ancy could be explained by the difference in the
study population and the study design, it seems ap-
parent that the impact of AIP in health and diseases
could be variable and should be better investigated.
Study strengths and limitations
The most important strength of the present study was
that it demonstrated, for the first time, that AIP at diag-
nosis is an independent predictor for CVA. However,
several issues should be considered as limitations. First,
the study was performed retrospectively and the clinical
outcomes of the patients were identified by reviewing
the hospital’s medical records. In addition, the optimal
cut-off value of AIP in predicting CVA could not be de-
fined by this study. Second, because only laboratory data
at initial diagnosis was used to calculate AIP, it is un-
clear whether dynamic changes in AIP levels might be
more relevant to the risk of CVAs. Third, the precise
mechanism of how AIP is associated with increased
CVA events could not be elucidated. Future prospective
studies with a larger number of patients will help verify
the results of this study and provide more information
regarding the potential of AIP in predicting CVA in
AAV.
Conclusions
AIP in AAV patients was significantly higher than that
in controls. Also, AIP ≥ 0.11 at diagnosis could predict
CVA occurrence during follow-up. These results suggest
that stringent surveillance is required in AAV patients
with AIP ≥ 0.11 regarding the occurrence of CVA.
Table 6 Comparison of medication usage between patients with AIP ≥ 0.11 and AIP < 0.11 during follow-up
All AAV patients
(N = 167)
AAV patients with AIP < 0.11
(N = 115)
AAV patients with AIP ≥ 0.11
(N = 52)
P-value
Medications administered during follow-up (N, (%))
Glucocorticoid 155 (92.8) 104 (90.4) 51 (98.1) 0.107
Cyclophosphamide 87 (52.1) 54 (47.0) 33 (63.5) 0.048
Rituximab 29 (17.4) 15 (13.0) 14 (26.9) 0.028
Azathioprine 82 (49.1) 52 (45.2) 30 (57.7) 0.135
Mycophenolate mofetil 22 (13.2) 13 (11.3) 9 (17.3) 0.288
Tacrolimus 11 (6.6) 6 (5.2) 5 (9.6) 0.289
Methotrexate 12 (7.2) 10 (8.7) 2 (3.8) 0.345
AIP Atherogenic index of plasma, AAV ANCA-associated vasculitis, ANCA Antineutrophil cytoplasmic antibody
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